Johnson & Johnson Newswire

Johnson & Johnson Newswire

Comprehensive Real-Time News Feed for Johnson & Johnson.

Results 1 - 20 of 3,635 in Johnson & Johnson

  1. Boyar Asset Management Inc. Has $2,391,000 Position in Johnson & JohnsonRead the original story w/Photo

    11 min ago | AmericanBankingNews.com

    Boyar Asset Management Inc. maintained its stake in shares of Johnson & Johnson during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission . The firm owned 23,274 shares of the company's stock at the end of the fourth quarter.

    Comment?

  2. Boston Financial Mangement Inc. MA Sells 221 Shares of Johnson & JohnsonRead the original story w/Photo

    1 hr ago | Daily Political

    Boston Financial Mangement Inc. MA decreased its position in Johnson & Johnson by 0.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission . The firm owned 169,621 shares of the company's stock after selling 221 shares during the period.

    Comment?

  3. Press Digest - Wall Street Journal - Feb 8Read the original story w/Photo

    1 hr ago | Reuters

    ... unit of Maple Financial Group.( on.wsj.com/1ojfxeV ) - After a tough end to 2015, big companies like Johnson & Johnson and Yahoo Inc are starting the new year with a tight rein on capital spending including layoffs, as they seek to cope with ...

    Comment?

  4. MomentumTHE More Things ChangeRead the original story

    3 hrs ago | American Reporter

    ... many products are still around today. Windex, for example. And Crisco. Drano. Franco American spaghetti. Johnson & Johnson baby powder. Lysol, which even back then was fighting "Infection... the sly and deadly enemy of every home." And Shredded ...

    Comment?

  5. Federal lawsuit filed against former FDA CommissionerRead the original story w/Photo

    3 hrs ago | WRIC-TV Richmond

    A federal lawsuit has been filed alleging the former FDA Commissioner who was well aware of problems with a popular antibiotic, but remained silent so she could profit. 8News has reported extensively about patients who say the drug Levaquin, which is often prescribed for everything from sinus infections to urinary tract infections, has been nothing but a prescription for pain.

    Comment?

  6. Big Companies Pull Back After Rough QuarterRead the original story w/Photo

    4 hrs ago | Wall Street Journal

    ... he continued resilience of the American consumer. A half-dozen large companies from medical-products giant Johnson & Johnson and tobacco maker Altria Group Inc. to Internet portal Yahoo Inc. have announced plans to cut...

    Comment?

  7. Donald Trump Makes His Populist Pitch in New HampshireRead the original story w/Photo

    8 hrs ago | MSNBC

    ... Jeb Bush would avoid taking on the issue as president because Woody Johnson, whose family founded Johnson & Johnson, served as his campaign chairman. "I have no friends, as far as I'm concerned," Trump said. "You know who my friends are? You're my ...

    Comment?

  8. EXCLUSIVE - "Carson: - Problematic' Donors Fill Debate AudienceRead the original story w/Photo

    10 hrs ago | Breitbart.com

    ... to us?" Trump used the drug companies as an example of special interests in politics. He said the head of Johnson & Johnson is one of Bush's top fundraisers. "I blame the RNC for this," Trump said about filling audience with donors. "I'm the one ...

    Comment?

  9. 4Big pharmaceutical companies are spending far more on marketing than researchRead the original story

    Feb 11, 2015 | The Washington Post

    ... are shown in orange, while the amounts spent on research and development are in blue. The biggest spender, Johnson & Johnson, shelled out $17.5 billion on sales and marketing in 2013, compared with $8.2 billion for R&D. In the top 10, only Roche ...

    Comment?

  10. New company makes push for ".md" domainRead the original story

    13 hrs ago | American Medical Association

    ... less than $10 per year. Still, MaxMD says several big names in health care already have registered names. Johnson & Johnson, for example, has registered more than 120 names, Finlay said. Meanwhile, you can access the National Institutes of Health ...

    Comment?

  11. Use General Dynamics' Recovery Rally to Bail Out of Longs: Real Money's Bruce KamichRead the original story

    14 hrs ago | TheStreet.com

    ... support line of the large horizontal channel on the S&P 500 weekly chart is being tested again and its... Johnson & Johnson (JNJ) saw a $15,762,000 sale (151,000 shares) at about a $104.10 average price. JNJ clos...

    Comment?

  12. Johnson & Johnson, ViaCyte Testing Possible Diabetes CureRead the original story w/Photo

    Thursday Feb 4 | CBS Local

    Johnson & Johnson, continuing its long quest for a Type 1 diabetes cure, is joining forces with biotech company ViaCyte to speed development of the first stem cell treatment that could fix the life-threatening hormonal disorder. They've already begun testing it in a small number of diabetic patients.

    Comment?

  13. Lab Criticized as 'Slow to React' in Bial's Fatal Drug TrialRead the original story

    Thursday Feb 4 | BioSpace

    ... suspended. FAAH inhibitors are being studied by other pharmaceutical companies. Janssen , a division of Johnson & Johnson ( JNJ ), is developing a FAAH inhibitor for social anxiety disorder, while Merck ( MRK ) and Pfizer ( PFE ) are developing FAAH ...

    Comment?

  14. Blueprint Medicines Appoints To Board Of DirectorsRead the original story

    Thursday Feb 4 | BioSpace

    ... held a variety of sales and management positions at Janssen Pharmaceuticals, Inc., a division of Johnson & Johnson, from 1988 to 1996. Mr. Coats holds a B.P.A. from . "I look forward to working with its board and talented management team to continue ...

    Comment?

  15. Johnson & Johnson Hands Over In-House Rival to ViaCyte, Gives Updates on Stem Cell Diabetes TrialRead the original story

    Wednesday Feb 3 | BioSpace

    ViaCyte Acquires Rights to BetaLogics Assets, Expanding and Extending Industry-Leading Portfolio for Stem Cell-Derived Approaches to Type 1 Diabetes - Preliminary data of STEP ONE clinical trial are promising - ViaCyte, Inc ., a leading, privately-held regenerative medicine company with the first pluripotent stem cell-derived islet replacement therapy for the treatment of type 1 diabetes in clinical-stage development, today announced that ViaCyte and Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, have agreed to consolidate the assets of the Janssen BetaLogics group into ViaCyte.

    Comment?

  16. Associated PressRead the original story

    Saturday | Samoa News

    Johnson & Johnson, continuing its long quest for a Type 1 diabetes cure, is joining forces with biotech company ViaCyte to speed development of the first stem cell treatment that could fix the life-threatening hormonal disorder. They've already begun testing it in a small number of diabetic patients.

    Comment?

  17. Top 5 web-only stories this weekRead the original story w/Photo

    Saturday | Tahoe Daily Tribune

    ... by ViaCyte shows the Encaptra delivery system, placed next to a quarter to give a size perspective. Johnson & Johnson, continuing its long quest for a type 1 diabetes cure, has agreed that biotech company ViaCyte can acquire BetaLogics' assets to ...

    Comment?

  18. Johnson & Johnson (JNJ) Stake Maintained by Bedrijfstakpensioenfonds Voor DE Media PNORead the original story w/Photo

    Saturday | AmericanBankingNews.com

    Bedrijfstakpensioenfonds Voor DE Media PNO maintained its position in shares of Johnson & Johnson during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 13,400 shares of the company's stock at the end of the fourth quarter.

    Comment?

  19. Johnson & Johnson (JNJ) Position Increased by Benedict Financial Advisors Inc.Read the original story w/Photo

    Saturday | AmericanBankingNews.com

    Benedict Financial Advisors Inc. boosted its position in Johnson & Johnson by 1.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission . The institutional investor owned 52,023 shares of the company's stock after buying an additional 883 shares during the period.

    Comment?

  20. Beech Hill Advisors Inc. Has $4,445,000 Stake in Johnson & JohnsonRead the original story w/Photo

    Saturday | AmericanBankingNews.com

    Beech Hill Advisors Inc. boosted its position in Johnson & Johnson by 633.5% during the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 43,275 shares of the company's stock after buying an additional 37,375 shares during the period.

    Comment?